3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
3
Tumor-Agnostic
2
Thoracic
2
Other solid neoplasm
2
Gastrointestinal
2
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
161
Fulvestrant
155
Trastuzumab
152
pembrolizumab
144
Letrozole
136
Carboplatin
118
pertuzumab
104
Cyclophosphamide
102
Capecitabine
102
Specimen Handling
101
Anastrozole
90
palbociclib
85
abemaciclib
81
Magnetic Resonance Spectroscopy
81
exemestane
76
Docetaxel
76
Tamoxifen
75
ribociclib
73
trastuzumab deruxtecan
69
Radiotherapy
61
Biopsy
59
Surveys and Questionnaires
56
Gemcitabine
52
130-nm albumin-bound paclitaxel
52
sacituzumab govitecan
50
olaparib
50
Standard of Care
49
Blood Specimen Collection
49
Taxes
47
Doxorubicin
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
brigimadlin
×
Breast
×
1 year
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn